Donald Trump’s eldest son, Donald Trump Jr., has officially invested in the so-called “Steroid Olympics” – officially known as the Enhanced Games, the competitive sporting event that promotes the use of performance-enhancing drugs to showcase the full ability of the human body.

The controversial event aims to dethrone Olympic athletes’ major records by paying its athletes to participate in any legally available performance-enhancing drugs.

On Thursday, the Enhanced Games revealed that 1789 Capital, Trump Jr.’s venture firm, plans to co-lead a multi-million-dollar investment round for the competitive sporting event (the exact number is unreleased).

In a statement, Trump Jr. declared, “For over 100 years, elites in charge of global sports have stifled innovation, crushed individual greatness, and refused to let athletes push the limits of what’s possible. That ends now.”

“The Enhanced Games represent the future – real competition, real freedom, and real records being smashed.”

He continued, “This is about excellence, innovation, and American dominance on the world stage – something the MAGA movement is all about.”

President of the Enhanced Games Aron D’Souza said, “We’re building something revolutionary — sports without hypocrisy, where the best can actually be the best.”

The Enhanced Games have also been backed by crypto investor Balaji Srinivasan, German billionaire Christian Angermayer and co-founder of PayPal Peter Thiel.

Last year, the Biden Administration released a statement condemning the Enhanced Games. The World Doping Association and the International Olympic Committee have also expressed concern regarding mental and physical health effects and the devaluing of the sport.

Within the first month of Trump’s second term, he has already made a variety of controversial decisions in regard to drugs and health policy.

Trump Jr. was recently investigated by Italian authorities over rare ducks killed during a hunting trip in Venice.

Read more about:
avatar

Article by Baila Eve Zisman

Leave a comment

Subscribe to the uInterview newsletter